- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00983359
Stereotactic Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Focal Therapy in the Treatment of Patients With 1-3 Brain Metastases
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
PURPOSE: This phase II trial is study how well stereotactic radiation therapy works in treating patients with brain metastases
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
OBJECTIVES:
Primary
- To determine the neurological death rate following the initiation of conformal stereotactic radiotherapy in patients with 1-3 brain metastases.
Secondary
- To determine the overall survival rate at 6 months.
- To determine the progression-free survival rate or brain metastases recurrence rate at 6 months.
- To determine the time to neurological death, time to systemic death, and Karnofsky decay time.
- To determine the frequency and severity of adverse events associated with conformal stereotactic radiotherapy.
OUTLINE: Patients undergo conformal stereotactic radiotherapy over 5 days to an area including 3 mm around the metastases or the surgical cavity. Patients may receive additional radiotherapy if symptomatic metastases emerge at different sites.
After completion of study treatment, patients are followed up at 1 and 2 months and then every 3 months thereafter.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Ohio
-
Columbus, Ohio, Stati Uniti, 43210-1240
- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Histology-confirmed cancer with 1 to 3 symptomatic brain metastases imaged by MRI/CT scans.
- Have cancer not originating in central nervous system (CNS)
- Karnofsky score of at least 60
- Given written consent
- At least 18 years of age
Exclusion Criteria:
- Prior whole brain radiotherapy or prior focal radiotherapy of the metastasis/es considered for this trial.
- Certain radiosensitive primary tumors such as small cell lung cancer, germ cell tumors, lymphoma, leukemia or multiple myeloma.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Treatment (conformal stereotactic radiation therapy)
Patients undergo conformal stereotatic radiation
|
Patients undergo conformal stereotatic radiation therapy QD (every day) over 5 days.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of Patients Dying of Neurological Death, Defined as Dying With Progressive Neurological Dysfunction Regardless of Systemic Disease Status
Lasso di tempo: Up to 5 years
|
Neurological death is defined as dying with progressive neurological dysfunction regardless of systemic disease status.
Patients wtih severe neurological disability who die of intercurrent illness will also be considered to have died of neurological death.
|
Up to 5 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-free Survival (PFS)
Lasso di tempo: Up to 5 years
|
Time from enrollment to first date of progressive or recurrent disease.
Worsening of neurological symptoms is considered indicative of neurological disease progression.
Patients who die of disease-related or treatment-related causes will be considered to have progressed at their date of death; i.e., not be considered 'censored'.
PFS will be considered censored only if no progression is noted or if the patient dies of a clearly non-cancer-related event such as accident.
|
Up to 5 years
|
|
Time to Neurological Death
Lasso di tempo: From time of enrollment up to 5 years
|
Time from enrollment to date of death directly due to brain metastases.
Deaths from other causes including hemorrhage or infection will be considered 'censored' observations in the setting of neurologic improvement or stabilization.
If the patient dies of any cause with worsening of neurologic symptoms, the death will be counted as an 'event' or neurological death.
|
From time of enrollment up to 5 years
|
|
Time to Systemic Death
Lasso di tempo: From time of enrollment up to 5 years
|
Descriptive analysis will be conducted using Kaplan-Meier survival analysis
|
From time of enrollment up to 5 years
|
|
Karnofsky Decay Time
Lasso di tempo: From time of enrollment up to 5 years
|
Time from enrollment to the date the patient's Karnofsky performance score drops below 60.
If the patient dies of any cause with no documentation of a drop in their Karnofsky score to less than 60, the date of death will be used as the date of worsening of the Karnofsky score.
A patient with a Karnofsky score of 60 or greater requires occasional assistance, but is able to care for most of his/her needs.
A patient's Karnofsky decay time will be considered censored if the patient is still under follow up with a Karnofsky score of 60 or greater and if the patient dies of a non-cancer-related cause.
|
From time of enrollment up to 5 years
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Mario Ammirati, MD, Ohio State University Comprehensive Cancer Center
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- OSU-06138
- NCI-2011-03139 (Identificatore di registro: Clinical Trials Reporting Program (CTRP))
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .